CoChat

Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities: Immune checkpoint inhibitor toxicity management

Open access
Roberts, Kate, Culleton, Vanessa, Lwin, Zarnie, O'Byrne, Kenneth, Hughes, Brett GM · 2017 · Asia-Pacific Journal of Clinical Oncology
Cited by 46

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Immune checkpoint inhibitors have recently emerged as an exciting new treatment paradigm across a broad spectrum of malignancies. This new class of agents also challenges oncologists with a unique set of immune-based toxicities. Early recognition and precise management of these toxicities can result in better outcomes, with minimization of toxicity and harm to the patient. This article provides a comprehensive review of immune-based toxicities caused by immune checkpoint inhibitors, including recommendations for their investigation and guidelines for specific management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/ajco.12698

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 46

Metadata

Authors
Roberts, K., Culleton, V., Lwin, Z., O'Byrne, K., & Hughes, B. G.
Venue
Asia-Pacific Journal of Clinical Oncology
Publisher
Wiley
Published
2017-07-12
Volume
13
Issue
4
Pages
277-288
ISSN
1743-7555 (ISSN-L)
OpenAlex
W2736008571
Cited by
46
References
11
FWCI
2.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities: Immune checkpoint inhibitor toxicity management. https://app.cochat.ai/papers/10.1111/ajco.12698
The paper
Roberts, K., Culleton, V., Lwin, Z., O'Byrne, K., & Hughes, B. G. (2017). Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities: Immune checkpoint inhibitor toxicity management. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.12698

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.